DexCom - >>> DexCom (DXCM) executed a 4-for-1 stock split on June 10, 2022. The company remains a leader in the diabetes care industry with its continuous glucose monitoring (CGM) devices. Bear in mind, the global market for CGMs is rapidly growing both as the incidence of diabetes rises and the adoption of these devices expands in the patient population.
According to an analysis by Grand View Research, the global CGM market is expected to reach a valuation of $11 billion by 2030, compared to its 2022 valuation of $7.8 billion. To give you an idea of the scale of DexCom's footprint in that market, the company reported revenue just shy of $3 billion in 2022, giving it an estimatedmarket share of about 40% globally.
And as of the end of 2022, roughly 1.7 million people around the world were using DexCom's CGM devices, a whopping increase of nearly half a million individuals compared to 2021. DexCom has built a steadily growing and profitable business around its CGM devices, and is in the process of releasing the latest version of its flagship product, the G7.
The new G7 CGM was just officially launched in the U.S. and has already been launched in key international markets including Europe, the U.K., and Asia. The product is billed as being 60% smaller than its predecessor, and with recent coverage expansion by Medicare, remains the most covered and reimbursed device of its kind.
2022 saw the company report earnings to the tune of $341 million, a 57% increase from 2021. DexCom's revenue rose 19% year over year, driven by revenue increases of 16% in the U.S. and 28% in international markets. Meanwhile, the healthcare company's operating income of $391 million represented a 250-basis point hike from 2021.
Another successful product launch and a strong track record of growth portend well for this market leader's continued expansion in the years ahead. Long-term shareholders can benefit in the process.